Ann Lab Med.  2023 Jan;43(1):117-119. 10.3343/alm.2023.43.1.117.

Development of Proliferating Cell Nuclear Antigen Autoantibodies With the Manifestation of Graft Versus Host Disease After Peripheral Blood Stem Cell Transplantation

• Kang H
• Cho SG
• Oh EJ

• KMID: 2551615
• DOI: http://doi.org/10.3343/alm.2023.43.1.117

Figure

• 

  Fig. 1 Timeline of the patient’s diagnosis and treatment history with representative ANA test images. The IIF test using Hep2 cells revealed a PCNA-like pattern. The small dots in the negative ANA test may be due to weakly reactive cytoplasmic antibodies or nonspecific antibodies against Hep2 substrates. Abbreviations: PCNA, proliferating cell nuclear antigen; Dx, diagnosis; CTx, chemotherapy; PBSCT, peripheral blood stem cell transplantation; GVHD, graft-versus-host disease; CVAD, cyclophosphamide/doxorubicin/vincristine/dexamethasone; HD-MTX-ARAC, high-dose methotrexate and cytarabine; DL-ICE, dexamethasone/L-asparaginase/ifosfamide/carboplatin/etoposide; ESHAP, etoposide/methylprednisolone/cytarabine/cisplatin; ECT, etoposide/cyclophosphamide/total body irradiation.

Reference

1. Min CK. 2011; The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigma. Korean J Hematol. 46:80–7. DOI: 10.5045/kjh.2011.46.2.80. PMID: 21747879. PMCID: PMC3128905.

2. Kuzmina Z, Gounden V, Curtis L, Avila D, Rnp Taylor T, Baruffaldi J, et al. 2015; Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria. Am J Hematol. 90:114–9. DOI: 10.1002/ajh.23885. PMID: 25363867. PMCID: PMC5535796.

3. Patriarca F, Skert C, Sperotto A, Zaja F, Falleti E, Mestroni R, et al. 2006; The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol. 34:389–96. DOI: 10.1016/j.exphem.2005.12.011. PMID: 16543073.

4. Hao B, Gao S, Sang YW, Wang L, Meng XQ, You JY. 2019; Potential value of autoantibodies as biomarkers of chronic graft-versus-host disease after allogeneic stem cell transplantation. J Zhejiang Univ Sci B. 20:849–60. DOI: 10.1631/jzus.B1900205. PMID: 31489804. PMCID: PMC6751484.

5. Yoon S, Moon H, Kim H, Hur M, Yun Y. 2022; Clinical performance of two automated immunoassays, EliA CTD Screen and QUANTA Flash CTD Screen Plus, for antinuclear antibody screening. Ann Lab Med. 42:63–70. DOI: 10.3343/alm.2022.42.1.63. PMID: 34374350. PMCID: PMC8368234.

6. Mahler M, Silverman ED, Fritzler MJ. 2010; Novel diagnostic and clinical aspects of anti-PCNA antibodies detected by novel detection methods. Lupus. 19:1527–33. DOI: 10.1177/0961203310375265. PMID: 20647252.

7. Guyomard S, Salles G, Coudurier M, Rousset H, Coiffier B, Bienvenu J, et al. 2003; Prevalence and pattern of antinuclear autoantibodies in 347 patients with non-Hodgkin's lymphoma. Br J Haematol. 123:90–9. DOI: 10.1046/j.1365-2141.2003.04587.x. PMID: 14510947.

8. Mahler M, Miyachi K, Peebles C, Fritzler MJ. 2012; The clinical significance of autoantibodies to the proliferating cell nuclear antigen (PCNA). Autoimmun Rev. 11:771–5. DOI: 10.1016/j.autrev.2012.02.012. PMID: 22381917.

9. Lee ZY, Think-You K. 2014; A case of small cell lung carcinoma with coexisting autoantibodies against proliferating cell nuclear antigen and centriole detected using the autoimmune target test. Lab Med Online. 4:218–21. DOI: 10.3343/lmo.2014.4.4.218.

10. Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix H, Halter J, et al. 2011; Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant. 46:1283–95. DOI: 10.1038/bmt.2011.35. PMID: 21441964. PMCID: PMC7094778.